Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107. https://doi.org/10.1056/NEJMoa1114287

Article  CAS  PubMed  Google Scholar 

Fox EJ, Buckle GJ, Singer B, Singh V, Boster A (2019) Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist. NeurolClinPract 9(1):53–63. https://doi.org/10.1212/cpj.0000000000000567

Article  Google Scholar 

Dello Russo C, Scott KA, Pirmohamed M (2021) Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. PharmacolTher 219:107710. https://doi.org/10.1016/j.pharmthera.2020.107710

Article  CAS  Google Scholar 

Lucchini M, Prosperini L, Buscarinu MC et al (2021) Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. J Neurol 268:2238–2245. https://doi.org/10.1007/s00415-021-10412-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L (2016) Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. MultScler 22(8):1061–1070. https://doi.org/10.1177/1352458515608961

Article  CAS  Google Scholar 

Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y (2018) Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol 9:5. https://doi.org/10.3389/fneur.2018.00005

Article  PubMed  PubMed Central  Google Scholar 

Dinoto A, Sartori A, Cheli M, Pasquin F, Baldini S, Bratina A, Bosco A, Manganotti P (2022) Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: prevalence, predicting factors and clinical outcomes. MultSclerRelatDisord 57:103357. https://doi.org/10.1016/j.msard.2021.103357

Article  CAS  Google Scholar 

Sainz de la Maza S, Sabin Muñoz J, Pilo de la Fuente B, Thuissard I, Andreu-Vázquez C, Galán Sánchez-Seco V, Salgado-Cámara P, Costa-Frossard L, Monreal E, Ayuso-Peralta L, García-Vasco L, García-Domínguez JM, Martínez-Ginés ML, Muñoz Fernández C, Díaz-Díaz J, Oreja-Guevara C, Gómez-Moreno M, Martín H, Rubio-Flores L, Blasco MR, Villar-Guimerans LM, Aladro Y; Dimethyl Fumarate Study Group (2022) Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. Mult Scler Relat Disord 59:103669. https://doi.org/10.1016/j.msard.2022.103669

Ravn J, Jensen HB, Kant M, Andersen PB, Góra MK, Sejbaek T (2022) Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. MultSclerRelatDisord 67:104081. https://doi.org/10.1016/j.msard.2022.104081

Article  CAS  Google Scholar 

Sainz de la Maza S, Medina S, Villarrubia N, Costa-Frossard L, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, Álvarez-Cermeño JC, Villar LM (2019) Factors associated with dimethyl fumarate-induced lymphopenia. J Neurol Sci 398:4–8. https://doi.org/10.1016/j.jns.2019.01.007.

Angeles PC, Robertsen I, Seeberg LT, Krogstad V, Skattebu J, Sandbu R, Åsberg A, Hjelmesaeth J (2019) The influence of bariatric surgery on oral drug bioavailability in patients with obesity: a systematic review. Obes Rev 20(9):1299–1311. https://doi.org/10.1111/obr.12869

Article  PubMed  PubMed Central  Google Scholar 

Edwards A, Ensom MH (2012) Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 46(1):130–136. https://doi.org/10.1345/aph.1Q414

Article  CAS  PubMed  Google Scholar 

Kingma JS, Burgers DMT, Monpellier VM, Wiezer MJ, Blussé van Oud-Alblas HJ, Vaughns JD, Sherwin CMT, Knibbe CAJ (2021) Oral drug dosing following bariatric surgery: general concepts and specific dosing advice. Br J ClinPharmacol 87(12):4560–4576. https://doi.org/10.1111/bcp.14913

Litjens NH, van Strijen E, van Gulpen C, Mattie H, van Dissel JT, Thio HB, Nibbering PH (2004) In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 4:22. https://doi.org/10.1186/1471-2210-4-22

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martins AR, Crisma AR, Masi LN, Amaral CL, Marzuca-Nassr GN, Bomfim LHM et al (2018) Attenuation of obesity and insulin resistance by fish oil supplementation is associated with improved skeletal muscle mitochondrial function in mice fed a high-fat diet. J Nutr Biochem 55:76–88. https://doi.org/10.1016/j.jnutbio.2017.11.012

Article  CAS  PubMed  Google Scholar 

Nagao H, Nishizawa H, Bamba T, Nakayama Y, Isozumi N, Nagamori S, Kanai Y, Tanaka Y, Kita S, Fukuda S, Funahashi T, Maeda N, Fukusaki E, Shimomura I (2017) Increased dynamics of tricarboxylic acid cycle and glutamate synthesis in obese adipose tissue: in vivo metabolic turnover analysis. J Biol Chem 292(11):4469–4483. https://doi.org/10.1074/jbc.M116.770172

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aron-Wisnewsky J, Doré J, Clement K (2012) The importance of the gut microbiota after bariatric surgery. Nat Rev GastroenterolHepatol 9(10):590–598. https://doi.org/10.1038/nrgastro.2012.161

Article  Google Scholar 

Zhang J, Zhang J, Wang R (2018) Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 50(3):357–368. https://doi.org/10.1080/03602532.2018.1497647

Article  CAS  PubMed  Google Scholar